Key result
Apixaban successfully resolved a left atrial appendage thrombus in a patient with persistent atrial fibrillation that was refractory to warfarin and dabigatran.
Why the study?
Does apixaban resolve left atrial appendage thrombus refractory to warfarin and dabigatran in a patient with persistent atrial fibrillation?
Case Report (n=1)
Does apixaban resolve left atrial appendage thrombus refractory to warfarin and dabigatran in a patient with persistent atrial fibrillation?
Apixaban may be an effective alternative for resolving left atrial appendage thrombi that are refractory to traditional anticoagulants like warfarin and direct thrombin inhibitors.
Apixaban may resolve warfarin-refractory LAA thrombus; hypothesis-generating and should not yet change practice.
The majority of embolisms associated with atrial fibrillation (AF) are from the left atrial appendage (LAA). To treat the existing thrombus, warfarin and novel anticoagulants have been used. However, there has been no clinical information regarding the difference of the effects of congealing the fibrinogenolysis system among these oral anticoagulants. Here, we report a case of persistent AF, in whom apixaban, factor Xa inhibitor resolved an LAA clot refractory to warfarin and direct thrombin inhibition. Factor Xa inhibitor, apixaban, could resolve the left appendage thrombosis refractory to warfarin and dabigatran.
No takes yet. Share an insight, caveat, or question.
Miwa et al. (2016) conducted a case report in Persistent atrial fibrillation with left atrial appendage thrombus (n=1). Apixaban vs. Warfarin and dabigatran (prior therapy) was evaluated on Resolution of left atrial appendage thrombus. Apixaban successfully resolved a left atrial appendage thrombus in a patient with persistent atrial fibrillation that was refractory to warfarin and dabigatran.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: